HEERLEN, Netherlands, March 10, 2022 /PRNewswire/ — Royal DSM, a global science-based company, today announces the acquisition, from March 10, 2022of 1,330,000 ordinary shares: 600,000 ordinary shares to cover commitments under equity compensation plans and 730,000 ordinary shares to cover stock dividend commitments as part of the 2021 final dividend. equals approximately €205 million based on the closing price of DSM ordinary share on Euronext Amsterdam on March 9, 2022.
The buyback of shares will be carried out within the limits of the powers granted to the Management Board by the General Meeting. The total number of ordinary shares to be repurchased under this program represents approximately 0.8% of the ordinary shares issued.
DSM has signed a discretionary management agreement with a bank to commence execution of the share buyback program on its behalf and to make business decisions under the agreement independently of DSM.
In accordance with the regulations, DSM will inform the market of the progress made in the execution of this program through weekly press releases. The share buyback program is expected to be completed in the second quarter of 2022.
Royal DSM is a global health, nutrition and bioscience company that applies science to improve the health of people, animals and the planet. DSM’s goal is to create a better life for everyone. DSM’s products and solutions address some of the world’s greatest challenges while simultaneously creating economic, environmental and societal value for all of its stakeholders – customers, employees, shareholders and society as a whole. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.
Or find us on:
For more information
This press release may contain forward-looking statements regarding DSM’s future (financial) performance and position. These statements are based on DSM’s current expectations, estimates and projections and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and, therefore, it should be understood that many factors could cause actual performance and position to differ materially from such statements. DSM has no obligation to update the statements contained in this press release, except as required by law. The English version of the press release is at the top.
Logo – https://mma.prnewswire.com/media/329419/dsm_logo.jpg
SOURCE Royal DSM